NovaTechs B.V. is a private company located in Maastricht, the Netherlands. Founded in 2020 by a team of researchers with expertise in advanced drug delivery technologies, including nanopharmaceuticals and polymeric hydrogels, the company focuses on the development of innovative liquid embolic systems for minimally invasive blood vessel occlusion.
The first application of this technology, NovaSeal™, is a hydrogel-based embolic solution designed to address key challenges in the treatment of hypervascular tumors in cancer patients, with a strong focus on safety, precision, and clinical usability.
NovaTechs is funded by the European Union through the Just Transition Fund (JTF) to support the research, validation, and preclinical development of NovaSeal™. This JTF-supported project enables the development of a bio-based, solvent-free, and metal-free embolic technology, contributing to safer medical treatments and a more sustainable medical technology ecosystem.
In addition to JTF support, NovaTechs has received funding through LIOF and Rabobank, strengthening the company's ability to translate scientific innovation into impactful clinical solutions.
